Status:
COMPLETED
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Merrimack Pharmaceuticals
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Detailed Description
Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard therapy. Phase 2: Pa...
Eligibility Criteria
Inclusion
- Patients with locally advanced or metastatic non-small cell lung cancer.
- Patients must be \>/= 18 years of age.
- Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.
Exclusion
- Patients with a recent history (within 5 years) of another malignancy.
- Patients who are pregnant or nursing.
- Patients with clinically significant heart failure.
- Patients with clinically significant eye or gastrointestinal abnormalities.
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT00994123
Start Date
February 1 2010
End Date
June 1 2015
Last Update
August 22 2016
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
Tucson, Arizona, United States, 85715
3
Loma Linda, California, United States, 92354
4
Sacramento, California, United States, 95817